Peptides DB
Research-centric peptide and protocol reference hub
The Washington PostNovember 10, 2026Regulatory

FDA tells GLP-1 makers to warn of potential vision loss side effect

Reported by The Washington Post. Read the original →

What the story says

The FDA has instructed manufacturers of GLP-1 medications to include warnings about a potential side effect related to vision loss.

Summarised by a model from The Washington Post's headline and its own description of the story. We did not read the article, and this is not our reporting — the link above is.

On file here

Every number below is counted from this library's own approved studies — the ones with a page you can open and check. Counts move as papers are filed.

What the headline doesn't tell you

  • This story is about a class — GLP-1 and incretin therapies — rather than one compound. We track 14 compounds in it, holding 373 studies between them, 163 in humans.

Counted, not written: each line is a sentence filled in from the study counts above. None of it is a judgement about the story or the compound.